Macroaxis: Personalized Investing

Personalized Investing and

Digital Wealth Optimization

Benchmark  United States  NYSE  10,890   58.62 Index Moved Up 0.54%  

Collecting data for MSTX

Mast price prediction Mast price prediction

Investment horizon:  
  30 Days    Login   to change
With this exotic module your can estimate the sentimental value of Mast Therapeutics Inc from the prospective of Mast response to recently generated media hype and the effects of current headlines on its competitors. The module also provides analysis of price elasticity to changes in media outlook on Mast over a specific investment horizon. See also Mast Backtesting, Mast Volatility, Mast Valuation, Mast Correlation, Mast History and Mast Performance

Mast hype analysis

Daily Expected returnPeriod VolatilityHype elasticityRelated hype elasticityAverage news densityRelated news densityNext Expected Hype
Price Moved Down 0.25% 2.58%No Change 0.00% Price Moved Up 0.38% 1 Events / Month1 Events / MonthUncertain
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
0.450.450.24% Mast price prediction down

Mast estimiated after-hype price volatility

Next price density
Expected price to next headline
December 20, 2014
Current Value
Downside upside
After-hype Price
Upside upside
Mast is abnormally risky asset. Analysis and calculation of next after-hype price of Mast Therapeutics is based on 1 month time horizon.

Mast hype timeline

Mast Therapeutics Inc is now traded for 0.45 . This company stock is not elastic to its hype. The average elasticity to hype of competition is 0.38. Mast Therapeutics Inc is projected to decline in value after the next headline with price expected to drop to 0.45. The average volatility of media hype impact on the company stock price is about 25800.0%. The price decrease on the next news is expected to be -0.24% where as daily expected return is now at -0.25%. The volatility of related hype on Mast is about 168.85% with expected price after next announcement by competition of 0.83. About 20.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.34. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Mast Therapeutics Inc recorded loss per share of 0.24. This company had not issued any dividends in recent years. The firm had 1:25 split on April 26, 2010. Given the investment horizon of 30 days, the next projected press release will be uncertain.
See also Mast Backtesting, Mast Volatility, Mast Valuation, Mast Correlation, Mast History and Mast Performance
Alpha Finder
Use alpha driven indicators to find investment opportunities after accounting for the market volatility
Find Alpha
Equity Screener
Evaluate performance of over 100,000 Stocks, Funds, and ETFs
Research Equities
Insiders Screener
Find insiders across different sectors to evaluate growth potential
Research Insiders
Mast Value
Change Benchmark  Embed   Timeline 

Mast related hype analysis

Short fall
At Risk
Gilead Sciences Inc(1.36)2 per month 0.00  0.26  0.00  2.76 (1.28) 5.34 
Amgen Inc(1.21)2 per month 0.00  0.15  0.00  2.53 (2.36) 4.72 
Celgene Corporation 2.09 2 per month 0.00  0.26  0.00  3.24 (2.28) 6.12 
Biogen Idec Inc(7.38)2 per month 0.00  0.36  0.00  6.25 (2.52) 9.61 
Regeneron Pharmaceuticals Inc 12.59 1 per month 0.00  0.15  0.00  3.11 (2.25) 6.77 
Alexion Pharmaceuticals Inc(0.57)2 per month 0.00 (0.02) 0.00  3.78 (2.99) 8.48 
Vertex Pharmaceuticals Incorporated 3.66 1 per month 0.00  0.13  0.00  3.05 (2.58) 7.84 
Illumina Inc 6.51 1 per month 0.00  0.07  0.00  3.36 (1.84) 6.12 
BioMarin Pharmaceutical Inc 1.61 2 per month 0.00  0.24  0.00  2.82 (2.96) 7.50 
Incyte Corporation(0.66)1 per month 0.00  0.16  0.00  4.52 (3.18) 7.90 


Risk Adjusted Returns Landscape
Live Efficient Frontier
Market Correlation Analysis
Watchlist Analysis
Financial Content
Portfolio Estimation and Projections
Portfolio Theme Builder

Research Modules

Equities Backtesting Analysis
Instant Retirement Optimizer
Cross-portfolio RSS and Mobile Access
Company, fund, and ETF Directory
Financial Advisor Directory
Insider and Manager Directory
Wealth Management

Services And Technology

Frequently Asked Questions
Quick Product Tour
Product Technology Overview
Solution Methodology
Plans and Pricing

Free Investor Tools

World Market Correlations
Instant Equity Comparator
Watchlist Analysis
Position Suggestions
Equity Alpha Analysis

About Us

About Macroaxis
Contact Us
Product Terms Of Use
Service Privacy Policy
Advertising Opportunities